Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies

Clinical Cancer Research

Volumn 17, Issue 24, 2011, Pages 7625-7633

  Ba, Qian ^a   Hao, Miao ^a   Huang, He ^b   Hou, Junmei ^a   Ge, Shichao ^a   Zhang, Zhuzhen ^a   Yin, Jun ^a   Chu, Ruiai ^a   Jiang, Hualiang ^b   Wang, Fudi ^a   Chen, Kaixian ^b   Liu, Hong ^b   Wang, Hui ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN A; CYCLIN B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IRON; IRON CHELATING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; THIOSEMICARBAZONE 24; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL LEVEL; CELL STRAIN HEK293; CELL STRAIN HEP3B; CELL STRAIN HEPG2; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG POTENCY; EXPERIMENTAL STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON BALANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON TRANSPORT; KNOCKOUT MOUSE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HEK293 CELLS; HEP G2 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IRON; IRON CHELATING AGENTS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; MOLECULAR STRUCTURE; THIOSEMICARBAZONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84055222075     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3099     Document Type: Article

References (43)

1. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 2010;30:3-16.
2. Cormier JN, Thomas KT, Chari RS, Pinson CW. Management of hepatocellular carcinoma. J Gastrointest Surg 2006;10:761-80. (Pubitemid 43711147)
3. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
4. Mendizabal M, Reddy KR. Current management of hepatocellular carcinoma. Med Clin North Am 2009;93:885-900, viii.
5. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010;16: 390-7.
6. Toyokuni S. Iron-induced carcinogenesis: the role of redox regulation. Free Radic Biol Med 1996;20:553-66. (Pubitemid 26097272)
7. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19-36. (Pubitemid 26049984)
8. Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci 2009;100:9-16.
9. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002. (Pubitemid 352019800)
10. Wu T, Sempos CT, Freudenheim JL, Muti P, Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201. (Pubitemid 38249333)
11. Kew MC. Hepatic iron overload and hepatocellular carcinoma. Cancer Lett 2009;286:38-43.
12. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K, et al. Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology 2006;219:41-52. (Pubitemid 43120705)
13. Deugnier Y, Turlin B, Loreal O. Iron and neoplasia. J Hepatol 1998;28 Suppl 1:21-5.
14. Chen J, Chloupkova M. Abnormal iron uptake and liver cancer. Cancer Biol Ther 2009;8:1699-708.
15. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 thesis revisited. Blood 1996;87: 3470-6.
16. Moyo VM, Makunike R, Gangaidzo IT, Gordeuk VR, McLaren CE, Khumalo H, et al. African iron overload and hepatocellular carcinoma (HA-7-0-080). Eur J Haematol 1998;60:28-34. (Pubitemid 28035757)
17. Mandishona E, MacPhail AP, Gordeuk VR, Kedda MA, Paterson AC, Rouault TA, et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in Black Africans. Hepatology 1998;27:1563-6. (Pubitemid 28264679)
18. Asare GA, Paterson AC, Kew MC, Khan S, Mossanda KS. Iron-free neoplastic nodules and hepatocellular carcinoma without cirrhosis in Wistar rats fed a diet high in iron. J Pathol 2006;208:82-90. (Pubitemid 43025706)
19. Kowdley KV. Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology 2004;127:S79-86. (Pubitemid 39423373)
20. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A 2006;103:14901-6. (Pubitemid 44527826)
21. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 2005;57:547-83. (Pubitemid 43036441)
22. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M, et al. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004;22:1553-63. (Pubitemid 41079792)
23. Richardson DR, Tran EH, Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 1995;86:4295-306.
24. Huang H, Chen Q, Ku X, Meng L, Lin L, Wang X, et al. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity. J Med Chem 2010;53:3048-64.
25. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008;14: 5519-30.
26. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006;2:406-14. (Pubitemid 44114917)
27. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8. (Pubitemid 32335941)
28. Le NT, Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood 2004;104:2967-75. (Pubitemid 39434989)
29. Yan X, Chua MS, Sun H, So S. N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Lett 2008;262:133-42.
30. Kijima H, Sawada T, Tomosugi N, Kubota K. Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 2008;8:167.
31. Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM, et al. Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood) 2009;234:693-702.
32. Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL, Yu HS, et al. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol 2009;135:1413-20.
33. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M, et al. Iron chelator research: past, present, and future. Curr Med Chem 2003;10: 983-95. (Pubitemid 36582243)
34. Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program 2006:42-7.
35. Fernandez-Pol JA. Transition metal ions induce cell growth in NRK cells synchronized in G1 by picolinic acid. Biochem Biophys Res Commun 1976;76:413-9.
36. Manning T, Kean G, Thomas J, Thomas K, Corbitt M, Gosnell D, et al. Iron chelators in medicinal applications-chemical equilibrium considerations in pharmaceutical activity. Curr Med Chem 2009;16:2416-29.
37. Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Jiang J, et al. HFE gene knockout produces mouse model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 1998;95:2492-7. (Pubitemid 28145969)
38. De Domenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol 2008;9:72-81.
39. Nick H, Allegrini PR, Fozard L, Junker U, Rojkjaer L, Salie R, et al. Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis. Exp Biol Med (Maywood) 2009;234:492-503.
40. Yu Y, Kovacevic Z, Richardson DR. Tuning cell cycle regulation with an iron key. Cell Cycle 2007;6:1982-94. (Pubitemid 47327885)
41. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A, et al. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 1993;53: 3968-75. (Pubitemid 23267697)
42. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells. Cancer Res 2009;69:948-57.
43. Vecchi C, Montosi G, Pietrangelo A. Huh-7: a human " hemochromatotic" cell line. Hepatology 2010;51:654-9.